Edwards Lifesciences Co. (NYSE:EW) VP Sells $185,200.00 in Stock

Edwards Lifesciences Co. (NYSE:EW) VP Daniel J. Lippis sold 2,500 shares of Edwards Lifesciences stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $74.08, for a total value of $185,200.00. Following the transaction, the vice president now owns 23,189 shares of the company’s stock, valued at $1,717,841.12. The trade was a 9.73 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Edwards Lifesciences Stock Down 1.8 %

Shares of EW opened at $72.81 on Thursday. The firm has a 50 day simple moving average of $69.81 and a two-hundred day simple moving average of $73.71. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The company has a market cap of $42.94 billion, a P/E ratio of 10.51, a P/E/G ratio of 3.63 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting analysts’ consensus estimates of $0.67. The company had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. Edwards Lifesciences’s revenue was up 8.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.59 EPS. Research analysts forecast that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on EW. JPMorgan Chase & Co. lifted their target price on Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a research note on Friday, October 25th. Oppenheimer reiterated an “outperform” rating and issued a $90.00 price objective on shares of Edwards Lifesciences in a report on Thursday, September 12th. Piper Sandler dropped their price objective on shares of Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Bank of America raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $82.00 to $90.00 in a report on Monday. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $70.00 price target on shares of Edwards Lifesciences in a report on Friday, October 11th. Sixteen research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat, Edwards Lifesciences has a consensus rating of “Hold” and an average target price of $79.40.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Wellington Management Group LLP increased its position in Edwards Lifesciences by 86.3% during the 3rd quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock worth $2,080,845,000 after purchasing an additional 14,610,123 shares in the last quarter. State Street Corp increased its holdings in shares of Edwards Lifesciences by 1.0% during the third quarter. State Street Corp now owns 26,265,633 shares of the medical research company’s stock worth $1,733,270,000 after buying an additional 256,538 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Edwards Lifesciences by 4.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 19,782,909 shares of the medical research company’s stock valued at $1,827,347,000 after acquiring an additional 809,605 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Edwards Lifesciences by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 13,521,147 shares of the medical research company’s stock valued at $889,050,000 after acquiring an additional 284,918 shares in the last quarter. Finally, Fisher Asset Management LLC grew its position in Edwards Lifesciences by 9.8% during the 3rd quarter. Fisher Asset Management LLC now owns 9,078,311 shares of the medical research company’s stock worth $599,078,000 after acquiring an additional 806,705 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.